Summary
Global Markets Direct’s, ‘Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Review, H1 2016’, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF)
- The report reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Post-Polycythemia Vera Myelofibrosis (PPV-MF) therapeutics and enlists all their major and minor projects
- The report assesses Post-Polycythemia Vera Myelofibrosis (PPV-MF) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Celgene Corporation
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
Incyte Corporation
Italfarmaco S.p.A.
JW Pharmaceutical Corporation
MEI Pharma, Inc.
Nippon Shinyaku Co., Ltd.
Novartis AG
Pfizer Inc.
Promedior, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Overview 7
Therapeutics Development 8
Pipeline Products for Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Overview 8
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics under Development by Companies 9
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Products under Development by Companies 12
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Companies Involved in Therapeutics Development 13
Celgene Corporation 13
F. Hoffmann-La Roche Ltd. 14
Gilead Sciences, Inc. 15
Incyte Corporation 16
Italfarmaco S.p.A. 17
JW Pharmaceutical Corporation 18
MEI Pharma, Inc. 19
Nippon Shinyaku Co., Ltd. 20
Novartis AG 21
Pfizer Inc. 22
Promedior, Inc. 23
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 33
buparlisib hydrochloride - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CWP-291 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
givinostat - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
glasdegib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
idelalisib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
itacitinib adipate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
LCL-161 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
momelotinib dihydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
NS-018 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
pomalidomide - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pracinostat - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
PRM-151 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
vismodegib - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Recent Pipeline Updates 68
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects 97
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products 98
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Product Development Milestones 99
Featured News & Press Releases 99
Dec 10, 2015: Promedior Presents Positive Phase 2 Data for PRM-151 in Myelofibrosis at ASH Annual Meeting 99
Appendix 101
Methodology 101
Coverage 101
Secondary Research 101
Primary Research 101
Expert Panel Validation 101
Contact Us 101
Disclaimer 102
List of Tables
Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Celgene Corporation, H1 2016 13
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 14
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Gilead Sciences, Inc., H1 2016 15
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Incyte Corporation, H1 2016 16
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Italfarmaco S.p.A., H1 2016 17
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by JW Pharmaceutical Corporation, H1 2016 18
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by MEI Pharma, Inc., H1 2016 19
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 20
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Novartis AG, H1 2016 21
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Pfizer Inc., H1 2016 22
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Pipeline by Promedior, Inc., H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 28
Number of Products by Stage and Route of Administration, H1 2016 30
Number of Products by Stage and Molecule Type, H1 2016 32
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Therapeutics - Recent Pipeline Updates, H1 2016 68
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Dormant Projects, H1 2016 97
Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Discontinued Products, H1 2016 98
List of Figures
Number of Products under Development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 11
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Top 10 Targets, H1 2016 25
Number of Products by Stage and Top 10 Targets, H1 2016 25
Number of Products by Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 27
Number of Products by Routes of Administration, H1 2016 29
Number of Products by Stage and Routes of Administration, H1 2016 29
Number of Products by Molecule Types, H1 2016 31
Number of Products by Stage and Molecule Types, H1 2016 31
